LH Laboratory Corp Of America Holdings Earnings and EPS analysis

EPS in 2025 (TTM): $8.72

Last Report Period Date: Mar 31, 2025

As of July 2025, according to Laboratory Corp Of America Holdings's latest financial report, the company's current EPS (TTM) is $8.72. In 2024, the company recorded an earnings per share (EPS) of $8.89, which represents an increase compared to its EPS of $4.8 in 2023. Laboratory Corp Of America Holdings's earnings per share for the quarterly report ending on Mar 31, 2025 was $2.54.

LH earnings history

Historical annual and quarterly earnings per share (EPS) data for Laboratory Corp Of America Holdings
EPS (TTM)
$8.72
EPS Growth YoY (Quarterly)
-6.3%
EPS (Quarterly)
$2.54
EPS Growth (Quarterly)
47.7%

The annual EPS in 2024 was $8.89, an increase of 85.2% from $4.8 in 2023. For the quarter ending Mar 31, 2025, the EPS was $2.54, showing a 6.3% decrease from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2025 is $8.72. In 2023, the annual EPS was $4.8, showing a decrease of 65.8% from 2022.

LH EPS growth

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-6.3%
EPS growth YoY
85.2%
EPS growth 3Y avg
-28.8%
EPS growth 5Y avg
1.1%

Laboratory Corp Of America Holdings has recorded a decrease in EPS of 6.3% over the last 12 months (YoY, quarterly). Over a three-year span, the company had an average EPS growth of -28.8% per year. Laboratory Corp Of America Holdings had an average annual EPS growth rate of 1.1% over the last 5 years. When measured over a ten-year period, LH's average EPS growth rate was 4%.

LH Earnings Waterfall

Breakdown of revenue, profit and net income for Laboratory Corp Of America Holdings

LH Earnings vs Peers

What are the earnings of LH compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
DGX Quest Diagnostics Inc 19.9 2.5% -21.1% 4.1%
LH Laboratory Corp Of America Holdings 30.39 85.2% -28.8% 1.1%
IDXX Idexx Laboratories Inc 51.76 5.9% 7.2% 16.7%
QGEN Qiagen NV 120.44 -74.7% -44.7% N/A
NEO Neogenomics Inc N/A 11.4% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.